Abstract:(1) Background: The sensitivity of head and neck squamous cell carcinoma (HNSCC) to ionizing radiation, among others, is determined by the number of cells with high clonogenic potential and stem-like features. These cellular characteristics are dynamically regulated in response to treatment and may lead to an enrichment of radioresistant cells with a cancer stem cell (CSC) phenotype. Epigenetic mechanisms, particularly DNA and histone methylation, are key regulators of gene-specific transcription and cellular plasticity. Therefore, we hypothesized that specific epigenetic targeting may prevent irradiation-induced plasticity and may sensitize HNSCC cells to radiotherapy. (2) Methods: We compared the DNA methylome and intracellular concentrations of tricarboxylic acid cycle metabolites in radioresistant FaDu and Cal33 cell lines with their parental controls, as well as aldehyde dehydrogenase (ALDH)-positive CSCs with negative controls. Moreover, we conducted a screen of a chemical library targeting enzymes involved in epigenetic regulation in combination with irradiation and analyzed the clonogenic potential, sphere formation, and DNA repair capacity to identify compounds with both radiosensitizing and CSC-targeting potential. (3) Results: We identified the histone demethylase inhibitor GSK-J1, which targets UTX (KDM6A) and JMJD3 (KDM6B), leading to increased H3K27 trimethylation, heterochromatin formation, and gene silencing. The clonogenic survival assay after siRNA-mediated knock-down of both genes radiosensitized Cal33 and SAS cell lines. Moreover, high KDM6A expression in tissue sections of patients with HNSCC was associated with improved locoregional control after primary (n = 137) and post-operative (n = 187) radio/chemotherapy. Conversely, high KDM6B expression was a prognostic factor for reduced overall survival. (4) Conclusions: Within this study, we investigated cellular and molecular mechanisms underlying irradiation-induced cellular plasticity, a key inducer of radioresistance, with a focus on epigenetic alterations. We identified UTX (KDM6A) as a putative prognostic and therapeutic target for HNSCC patients treated with radiotherapy.

Research Progress in the mechanism of histone deacetylase inhibitors as radiosensitizers

HDAC-an important target for improving tumor radiotherapy resistance

HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.

Research Progress in the Mechanism of Molecular Targeted Anti-tumor Drugs

Effects of a novel HDAC6-selective inhibitor's radiosensitization on cancer cells

Advances in targeting histone deacetylase for treatment of solid tumors

Advances of study in affecting factors of tumor radiosensitivity

Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects

Targeting histone deacetylases for cancer therapy: Trends and challenges

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair

Molecular mechanisms of sensitivity and resistance to radiotherapy

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

Epigenetic Targeting to Overcome Radioresistance in Head and Neck Cancer

The application of histone deacetylases inhibitors in glioblastoma

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

The Mechanism of Ubiquitination or Deubiquitination Modifications in Regulating Solid Tumor Radiosensitivity